(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 8.4% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Vertex Pharmaceuticals's revenue in 2025 is $11,020,100,000.On average, 10 Wall Street analysts forecast VRTX's revenue for 2025 to be $3,045,692,705,436, with the lowest VRTX revenue forecast at $3,020,439,476,139, and the highest VRTX revenue forecast at $3,078,473,986,533. On average, 10 Wall Street analysts forecast VRTX's revenue for 2026 to be $3,334,336,587,316, with the lowest VRTX revenue forecast at $3,193,926,711,635, and the highest VRTX revenue forecast at $3,596,855,695,083.
In 2027, VRTX is forecast to generate $3,599,564,057,831 in revenue, with the lowest revenue forecast at $3,434,258,917,931 and the highest revenue forecast at $3,809,606,101,550.